Correction: Initial activities and prospects of MIRAY1: a youth-driven, society-endorsed initiative to cultivate future breast cancer physicians
Hiroko Masuda, Takaaki Konishi, Mai Onishi, Aki Ito et autres
0 citationsBreast Cancer
Tsutomu Iwasa
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
170Publications signalées
4367Citations signalées
6Affiliations récentes
Institutions déclarées
Domaines associés
HER2/EGFR in Cancer ResearchAdvanced Breast Cancer TherapiesCancer Treatment and PharmacologyCancer Immunotherapy and BiomarkersBreast Cancer Treatment Studies
Publications récentes
Initial activities and prospects of MIRAY1: a youth-driven, society-endorsed initiative to cultivate future breast cancer physicians
Hiroko Masuda, Takaaki Konishi, Mai Onishi, Aki Ito et autres
0 citationsBreast Cancer
Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALD
Norikazu Masuda, Shigehira Saji, Yasuyuki Kojima, Masahiro Kitada et autres
0 citationsBreast Cancer Research and Treatment
Abemaciclib rechallenge after progression on abemaciclib plus endocrine therapy in patients with hormone receptor-positive HER2-negative metastatic breast cancer: results from the phase II again study (WJOG14220B)
Meiko Nishimura, Takahiro Kogawa, Keiji Sugiyama, Yukinori Ozaki et autres
0 citationsBreast Cancer Research and Treatment
Quality of life with palbociclib plus tamoxifen in hormone receptor-positive, HER2-negative advanced breast cancer: results from PATHWAY, an Asian international, double-blind, randomized phase 3 trial
Takashi Yamanaka, J K Sohn, Kazuki Sudo, Hirofumi Mukai et autres
0 citationsBreast Cancer
Quality-of-life assessment in the randomized JBCRG-M06/EMERALD study of eribulin plus dual HER2 blockade in HER2-positive locally advanced or metastatic breast cancer
Tsuguo Iwatani, Norikazu Masuda, Shigehira Saji, Takuhiro Yamaguchi et autres
0 citationsBreast Cancer
Palbociclib plus tamoxifen ± goserelin in women with hormone receptor (HR)-positive, HER2-negative advanced breast cancer (BC): PATHWAY, an Asian international double-blind randomized phase 3 trial—Final overall survival (OS) analysis.
Yen-Shen Lu, Emi Noguchi, Takashi Yamanaka, Hirofumi Mukai et autres
0 citationsJournal of Clinical Oncology
A randomized phase II study of pembrolizumab plus paclitaxel with or without bevacizumab in PD-L1–positive recurrent triple-negative breast cancer previously treated with perioperative immune checkpoint inhibitors: WJOG16522B (PRELUDE) trial.
Kazuki Nozawa, Yukinori Ozaki, Tomohiro Oshino, Kaori Terata et autres
0 citationsJournal of Clinical Oncology
Abemaciclib Rechallenge after Progression on Abemaciclib plus Endocrine Therapy in Patients with Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer: Results from the Phase Ⅱ AGAIN Study (WJOG14220B)
Meiko Nishimura, Takahiro Kogawa, Keiji Sugiyama, Yukinori Ozaki et autres
0 citationsResearch Square
BRCA1/2 Reversion Mutations in Japanese Patients with Metastatic Breast Cancer Progressing on Olaparib: OLIVE (WJOG15321B)
Hitomi Sakai, Rika Kusumoto-Matsuo, Mari Hosonaga, Kazuki Nozawa et autres
0 citationsBreast Cancer
Sacituzumab govitecan in Japanese participants with HR+/HER2− metastatic breast cancer: primary results from the phase II ASCENT-J02 study
Akihiko Shimomura, Takahiro Kogawa, Koji Matsumoto, Junichiro Watanabe et autres
0 citationsJapanese Journal of Clinical Oncology
Spatial single-cell proteotyping reveals immunotherapy-resistant features within the complex tumor microenvironment of metastatic NSCLC
Kohsuke Isomoto, Koji Haratani, Takahiro Tsujikawa, Shuta Tomida et autres
0 citationsJournal of Clinical Investigation
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.